Navigation Links
Haemacure and Angiotech Enter License, Distribution and Supply Agreements for Haemacure's All-Human Fibrin Sealant and Thrombin Products
Date:6/3/2009

al sale of an approved Angiotech product containing thrombin procured from Haemacure. Angiotech has an option to renew the agreement for an additional five years.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's proprietary, lead product candidate is a fibrin sealant in late-stage clinical trials. Haemacure's proprietary, second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on the use of fibrin sealant in aesthetics, adhesion prevention, combination with biomaterials, drug delivery, regenerative medecine, skin graft fixation for burn injuries, and wound healing.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit its website at www.angiotech.com.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic condi
'/>"/>

SOURCE HAEMACURE CORPORATION
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Haemacure Update on Proposed Collaboration and Bridge Financing
2. Haemacure Signs Term Sheet for Proposed Collaboration and Bridge Financing
3. Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company
4. Haemacure Restructures - Seeks Financing or Sale of the Company
5. Haemacure to Present at the 11th Annual BIO CEO & Investor Conference
6. Haemacure Announces Fiscal 2008 Results
7. Haemacures Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury
8. Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
9. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
10. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
11. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... In a world enveloped in technological ... lessened, and due to the intrusion of cell ... has eroded. According to Web MD, one in ... http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This remarkably high number lowers ... amount, leading not only to dissatisfied employers, but ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. ... to acquire a second language, new research suggests. But anyone ... gain a brain boost, the small study finds. ... study co-author Ping Li, co-director of the Center for Brain, ... more interesting, Li said, that "the brain networks of the ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 VogueQueen.com is ... items for ladies across the world. As the premier ... accessories, VogueQueen.com is proud to release a huge selection ... high quality outfits, it is also providing many beautiful ... VogueQueen prom gowns at discounted prices. , “VogueQueen.com ...
(Date:11/27/2014)... Texas (PRWEB) November 27, 2014 ... report on Global Insulin industry. For an overview ... definition, classification, application, industry chain structure, industry overview, ... on global Insulin industry covers information on ... process, product cost structure and much more. ...
Breaking Medicine News(10 mins):Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3
... Feb. 3 Noticing a few extra hairs in your,comb ... conceal areas of,thinning hair rather than a fashion choice? Are ... growth? If you answered,yes to any of these questions, you ... of hair loss. But to whom should you turn for ...
... importance of physical activities to improve balance , , SUNDAY, Feb. ... one in three seniors over age 65, and almost one ... this year -- in some cases, leading to serious disability ... their balance and reduce their risk of falls are expected ...
... patient safety enhancements to dramatically reduce errors and improve ... obstetrical care. , Edmund F. Funai, M.D., associate ... Sciences at Yale, will present preliminary results from this ... Meeting on February 2 in Dallas, Texas. , An ...
... February is American Heart Month, a,time when experts say ... to,reduce risk for heart disease. Here,s more on how ... but just eat the right kind for good heart ... Association of Margarine,Manufacturers at: http://media.medialink.com/WebNR.aspx?story=34443 , Registered ...
... potential for patients with specific gene mutations, researchers find ... sorafenib shows promise in the treatment of people with ... U.S. researchers. , Previous research has shown that sorafenib ... -- is effective against acute myeloid leukemia cells that ...
... LOUISVILLE, Ky., Feb. 1 Ventas, Inc. ... it has completed the,sale of 4,485,000 shares of ... registration statement. The amount includes 585,000 shares,of common ... of the,underwriter,s overallotment option. The Company received net ...
Cached Medicine News:Health News:Don't Let Hair Loss Tangle You Up: Dermatologists Can Identify Common Hair Disorders and Offer Solutions 2Health News:Don't Let Hair Loss Tangle You Up: Dermatologists Can Identify Common Hair Disorders and Offer Solutions 3Health News:Don't Let Hair Loss Tangle You Up: Dermatologists Can Identify Common Hair Disorders and Offer Solutions 4Health News:Don't Let Hair Loss Tangle You Up: Dermatologists Can Identify Common Hair Disorders and Offer Solutions 5Health News:Don't Let Hair Loss Tangle You Up: Dermatologists Can Identify Common Hair Disorders and Offer Solutions 6Health News:Toll-Free Hotline to Help Seniors Avoid Falls 2Health News:New strategy helps reduce errors in obstetrical care 2Health News:Sorafenib Slows Growth of Some Leukemias 2Health News:Ventas Completes Previously Announced Sale of Common Stock 2Health News:Ventas Completes Previously Announced Sale of Common Stock 3Health News:Ventas Completes Previously Announced Sale of Common Stock 4
(Date:11/26/2014)... , Nov. 26, 2014  Cohen, Placitella & ... of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" ... the period from January 31, 2011 through November ... Nymox and certain of its officers and directors ... violation of Sections 10(b) and 20(a) of the ...
(Date:11/26/2014)... 2014   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... CEO of Regulus, will present a company overview at ... at the New York Palace Hotel on Wednesday, December ... be webcast at the time of the presentation and ...
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... Calif., May 9, 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ... the fiscal quarter ended March 31, 2011, and provided ... ended March 31, 2011 and 2010, as reported in ... States, was $8.4 million and $13.4 million, respectively.  At ...
... Inc. (OTC: LPTN), the category leader in bioactive-lipid-targeted therapeutics, ... available for on-demand viewing. LINK: www.retailinvestorconferences.com ... button. Lpath, Inc.,s presentation will be available ... from the "virtual trade booth" for the next three ...
Cached Medicine Technology:Alexza Reports 2011 First Quarter Financial Results and Provides Business Update 2Alexza Reports 2011 First Quarter Financial Results and Provides Business Update 3Alexza Reports 2011 First Quarter Financial Results and Provides Business Update 4Alexza Reports 2011 First Quarter Financial Results and Provides Business Update 5Alexza Reports 2011 First Quarter Financial Results and Provides Business Update 6Alexza Reports 2011 First Quarter Financial Results and Provides Business Update 7Alexza Reports 2011 First Quarter Financial Results and Provides Business Update 8Alexza Reports 2011 First Quarter Financial Results and Provides Business Update 9Lpath, Inc. CEO Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2Lpath, Inc. CEO Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: